Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	53
Overall Study	STARTED	Spesolimab low dose group	53
Overall Study	STARTED	Spesolimab medium dose group	52
Overall Study	STARTED	Spesolimab high dose group	51
Overall Study	COMPLETED	Placebo	21
Overall Study	COMPLETED	Spesolimab low dose group	20
Overall Study	COMPLETED	Spesolimab medium dose group	20
Overall Study	COMPLETED	Spesolimab high dose group	17
Overall Study	NOT COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	Spesolimab low dose group	33
Overall Study	NOT COMPLETED	Spesolimab medium dose group	32
Overall Study	NOT COMPLETED	Spesolimab high dose group	34

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05819398/flow